Statements (12)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
1445981-36-1
|
| gptkbp:clinicalTrialPhase |
Phase 1 (as of 2023)
|
| gptkbp:developedBy |
Xenon Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
XEN-D0501
|
| gptkbp:intendedUse |
treatment of neuropathic pain
|
| gptkbp:mechanismOfAction |
selective Nav1.7 sodium channel blocker
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:bfsParent |
gptkb:Pila_Pharma
|
| gptkbp:bfsLayer |
8
|